Riverview Capital Advisers’s Imunon IMNN Stock Holding History

Riverview Capital Advisers’s Portfolio IMNN Stock Details IMNN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Hold	34,364	–	–	0.07%	79
2026 Q1	$248K	Hold	34,364	–	–	0.08%	74
2025 Q4	$248K	Hold	34,364	–	–	0.08%	80
2025 Q3	$248K	Buy	34,364 +33,466	+3,727%	+$224K	0.07%	85
2025 Q2	$9.37K	Buy	+898	New	+$12.3K	﹤0.01%	95

Other funds holding IMNN

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Riverview Capital Advisers's IMNN Position: Q2 2026 in Review

Riverview Capital Advisers held its Imunon (IMNN) position steady in Q2 2026 at 34,364 shares worth $248K. The position accounts for 0.07% of the portfolio, ranked #79.

Riverview Capital Advisers first reported a position in IMNN in Q2 2025 and has held it in 5 quarters since. 23 funds tracked by Wall St. Rank hold IMNN as of Q2 2026.

Riverview Capital Advisers held 34,364 shares of Imunon worth $248K as of Q2 2026.
Riverview Capital Advisers left its Imunon share count unchanged in Q2 2026.
Imunon made up 0.07% of Riverview Capital Advisers's portfolio in Q2 2026, its #79 holding.
Riverview Capital Advisers first reported a position in Imunon in Q2 2025 and has held it in 5 quarters since.
23 funds tracked by Wall St. Rank held Imunon as of Q2 2026.

Based on Riverview Capital Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.